Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q2 FY2019 Earnings Presentation
14 slides from Camlin Fine Sciences's earnings presentation, Nov 6, 2018
Slide 1: Stock exchange intimation letter for Q2 results
>Camlin Fine Sciences Date: 06/11/2018 To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai — 400 001 Ref: Company Scrip Code: 532834 To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLIN
Slide 2: Bringing Science to Everyday Life
2018 BRINGING SCIENCE BRINGING TO SCIENCE EVERYDAY TO EVERYDAYLIFE LIFE
Slide 3: Investors' Presentation Q2 FY 2019
Unaudited Quarterly Financial Statements November 6, 2018 Q2 FY 2019 Investors’ Presentation
Slide 4: Financial Highlights – Q2 2019 - Consolidated
Financial Highlights – Q2 2019 - Consolidated INR Crores • Consolidated total revenues for the quarter were at INR 201.34 crore showing a growth of 10.99% & 37.77% as compared to previous quarter and corresponding last year quarter respectively. • Robust growth in the blends business worldwide and s
Slide 5: Financial Highlights – Q2 2019 – Standalone India
Financial Highlights – Q2 2019 – STANDALONE INDIA INR Crores • Total revenue for the Quarter stood at INR 118.82 crore representing growth of 10.17% & 36.60% as compared to previous quarter and corresponding last year quarter respectively. • Completed the de-bottlenecking of the capacity of Performa
Slide 6: Subsidiary Operations – CFS Mexico
Subsidiary Operations – CFS Mexico INR Crores • Manufactures Blends. • CFS Mexico covers the business of the subsidiaries in Mexico, Peru, Guatemala, Colombia & Republic of Dominic. • Value of EBITDA has been maintained over last quarter even though gross margin was impacted due to change in product
Slide 7: Subsidiary Operations – CFS Europe
Subsidiary Operations – CFS Europe INR Crores • CFS Europe manufactures diphenols. • Annual maintenance shut down was completed in a record time of 10 days which had a slight impact on the revenues. • Capacity utilization achieved at 82.40%. • During the quarter, the company has initiated cost reduc
Slide 8: Subsidiary Operations – CFS Brazil
Subsidiary Operations – CFS Brazil INR Crores • Manufactures Blends. • Revenue has grown due to launch of new products in animal nutrition and better penetration of markets. • Subsidiary has turned EBITDA positive in current quarter. • Inspite of currency devaluation has shown a better overall perfo
Slide 9: Subsidiary Operations – CFS Wanglong
Subsidiary Operations – CFS Wanglong INR Crores • Manufactures Vanillin in China – Manufacturing started at the end of Q2 FY 18. • Revenues were low due to the seasonality of Vanillin business. • Turnover is expected to grow as was observed in Q3 and Q4 of FY 18.
Slide 10: Subsidiary Operations – CFS North America
Subsidiary Operations – CFS North America INR Crores • Manufactures Blends. • Subsidiary has launched new products in natural anti-oxidants and animal nutrition, positive impact of these initiatives will be seen in near future.
Slide 11: Other Operating Subsidiaries; Update on Dahej Project
Other Operating Subsidiaries • Business of CFS Argentina and CFS Chile have commenced in the current quarter. CFS Pahang (Singapore) is in the process of registering its products in Malaysia. Update on Dahej Project • With the financial closure of funding required for Dahej Project with subscription
Slide 12: Financial Results for Q2 FY 2019
Financial Results for Q2 FY 2019 • The Board of Directors, at its meeting in Mumbai on November 6, 2018, approved the financial results for the quarter ended September 30, 2018, which have been filed with the Stock Exchanges.
Slide 13: Invitation for Investors' Meet
Invitation for Investors’ Meet We are pleased to inform that we are conducting an investors’ meet instead of an earnings call. The meet is organized on November 16, 2018 Thursday at Oyster, Hotel Sahara Star, Near Domestic Airport, Vile Parle 3.30 pm onwards which will be followed by high tea. In th
Slide 14: Disclaimer
Disclaimer This presentation has been prepared by Camlin Fine Sciences Limited (the “Company”) solely for information purposes, without regard to any specific objectives, financial situations or informational needs of any particular person. All information contained has been prepared solely by the C
Camlin Fine Sciences — Q2 FY2019 Earnings Presentation on 6ix